Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MBG453 plus azacitidine vs placebo plus azacitidine in higher-risk myelodysplastic syndrome
jRCT2080224784Phase 2Completed
- Sponsor
- Novartis
- Start
- Jul 2019
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
Phase 2, randomised, double-blind trial in myelodysplastic syndrome (MDS) comparing MBG453 + azacitidine with Placebo + azacitidine (2 arms). Primary endpoints: progression-free survival and complete response rate. Started Jul 2019; status: completed.
02
Drugs
sabatolimab
03
Conditions
myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on jRCT2080224784.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080224784.